Patents by Inventor Michelle Georgiou

Michelle Georgiou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11065195
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 20, 2021
    Assignee: MC2 Therapeutics Limited
    Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
  • Publication number: 20210015831
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 21, 2021
    Applicant: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
  • Publication number: 20210000796
    Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypetides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: DRUG DELIVERY SOLUTIONS APS
    Inventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
  • Patent number: 10806721
    Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 20, 2020
    Assignee: DRUG DELIVERY SOLUTIONS APS
    Inventors: Torkil Menne, Johan Selmer, Jesper Lange, Michelle Georgiou, Derek Wheeler, David Evans
  • Publication number: 20190358151
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
    Type: Application
    Filed: February 27, 2019
    Publication date: November 28, 2019
    Applicant: DRUG DELIVERY SOLUTIONS LIMITED
    Inventors: Derek WHEELER, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
  • Publication number: 20190321336
    Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 24, 2019
    Inventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
  • Patent number: 10265265
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: April 23, 2019
    Assignee: DRUG DELIVERY SOLUTIONS LIMITED
    Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
  • Publication number: 20080234239
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
    Type: Application
    Filed: March 14, 2008
    Publication date: September 25, 2008
    Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
  • Publication number: 20080227759
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
    Type: Application
    Filed: September 27, 2007
    Publication date: September 18, 2008
    Inventors: Derek Wheeler, Steen Sindet-Pedersen, David F. Steele, Michelle Georgiou
  • Publication number: 20060228408
    Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.
    Type: Application
    Filed: July 30, 2004
    Publication date: October 12, 2006
    Inventors: William Charman, Monica Dias, Michelle Georgiou, Philip Guffogg, Christopher Porter, Colin Pouton, Fraser Steele, Derek Wheeler